Synmosa Biopharma Corporation

4114

TW0004114004

Pharmaceuticals

End-of-day quote Taipei Exchange Other stock markets 23:00:00 09/05/2024 BST			5-day change	1st Jan Change
39.55 ^TWD	+1.15%		+2.06%	+2.33%

03-29	Synmosa Biopharma Corporation Reports Earnings Results for the Full Year Ended December 31, 2023	CI
01-16	Synmosa Biopharma Corporation Announces Changes in Fifth Session of the Remuneration Committee	CI

Synmosa Biopharma Corporation announced that it expects to receive TWD 950 million in funding

June 20, 2023

Synmosa Biopharma Corporation announced a private placement of 25,000,000 common shares for a price of TWD 38 per share for the gross proceeds of TWD 9500 million on June 21, 2023.

Latest news about Synmosa Biopharma Corporation

Synmosa Biopharma Corporation Reports Earnings Results for the Full Year Ended December 31, 2023	03-29	CI
Synmosa Biopharma Corporation Announces Changes in Fifth Session of the Remuneration Committee	01-16	CI
Synmosa Biopharma Corporation Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	11-12	CI
Synmosa Biopharma Corporation Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	10/08/23	CI
Synmosa Biopharma Corporation Announces Cash Dividend, Payable on September 15, 2023	24/07/23	CI
Synmosa Biopharma Corporation Appoints Tu, San-Chien as Additional Independent Director	13/07/23	CI
Synmosa Biopharma Corporation Appoints Tu, San-Chien as Member of the Audit Committee	13/07/23	CI
Synmosa Biopharma Corporation announced that it expects to receive TWD 950 million in funding	20/06/23	CI
Synmosa Biopharma Corporation Reports Earnings Results for the First Quarter Ended March 31, 2023	15/05/23	CI
Synmosa Biopharma Corporation Reports Earnings Results for the Full Year Ended December 31, 2022	31/03/23	CI
Synmosa Biopharma Corporation Approves Dividend for the Year Ended December 31, 2022	13/03/23	CI
Synmosa Biopharma Corporation Announces Changes of Corporate Governance Officer	18/01/23	CI
Synmosa Biopharma Corporation Provides Earnings Guidance for the Year 2022	28/11/22	CI
Synmosa Biopharma Corporation Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022	11/11/22	CI
Synmosa Biopharma Corporation Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2022	11/08/22	CI
Synmosa Biopharma Corporation Announces Changes to the Compensation Committee	22/06/22	CI
Synmosa Biopharma Corporation Announces Cash Dividends, Payable on August 15, 2022	22/06/22	CI
Synmosa Biopharma Corporation Announces Wang Chien-Jen as Independent Director	25/05/22	CI
Tranche Update on Synmosa Biopharma Corporation's Equity Buyback Plan announced on March 29, 2022.	13/05/22	CI
Synmosa Biopharma Corporation's Equity Buyback announced on May 29, 2022, has closed with 4,000,000 shares, representing 1.35% for TWD 108.97 million.	12/05/22	CI
Synmosa Biopharma Corporation Reports Earnings Results for the First Quarter Ended March 31, 2022	12/05/22	CI
Synmosa Biopharma Corporation Reports Earnings Results for the Full Year Ended December 31, 2021	29/03/22	CI
Synmosa Biopharma Corporation announces an Equity Buyback for 4,000,000 shares, for TWD 1,177.47 million.	29/03/22	CI
Synmosa Biopharma Corporation authorizes a Buyback Plan.	28/03/22	CI
Synmosa Biopharma Corporation Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2021	09/11/21	CI

Chart Synmosa Biopharma Corporation

Duration

Period

More charts

SYNMOSA BIOPHARMA CORPORATION is a Taiwan-based company principally engaged in the manufacture and sales of various kinds of pharmaceuticals and medical equipment. The Company's main products include respiratory drugs, cardiovascular and urinary drugs, gastrointestinal drugs, hormones, anti-tumor drugs, antibiotics and health products. The Company is also involved in the manufacture and sales of various kinds of cosmetics and animal medicines, as well as various kinds of chemical food additives and beverages. The Company distributes its products in domestic market and to overseas markets.

Sector

Pharmaceuticals

More about the company

Income Statement Evolution

More financial data

Quarterly revenue - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

	1st Jan change	Capi.
SYNMOSA BIOPHARMA CORPORATION	+2.33%	465M
ELI LILLY AND COMPANY	+30.38%	684B
NOVO NORDISK A/S	+26.51%	568B
JOHNSON & JOHNSON	-4.36%	361B
MERCK & CO., INC.	+19.30%	329B
ABBVIE INC.	+3.73%	284B
ASTRAZENECA PLC	+16.70%	240B
NOVARTIS AG	+8.78%	208B
ROCHE HOLDING AG	-7.93%	200B
AMGEN INC.	+7.68%	166B

Other Pharmaceuticals